Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 17, 2017

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Onvansertib

Onvansertib orally

DRUG

Cytarabine

subcutaneously

DRUG

Decitabine

intravenously

Trial Locations (9)

14263

Roswell Park Cancer Institute, Buffalo

22031

Virginia Cancer Specialists - Fairfax Office, Fairfax

55407

Allina Health Virginia Piper Cancer Institute, Minneapolis

66205

University of Kansas Cancer Center, Westwood

75390

University of Texas Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

90095

University of California Los Angeles, Los Angeles

98109

Seattle Cancer Care Alliance, Seattle

06510

Yale University, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cardiff Oncology

INDUSTRY

NCT03303339 - Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter